Daniel A Haber Selected Research

Oncogene Addiction

2/2015	Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.
3/2012	Systematic identification of genomic markers of drug sensitivity in cancer cells.
7/2008	Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.
3/2007	Epidermal growth factor receptor mutations in lung cancer.
7/2006	"Oncogenic shock": explaining oncogene addiction through differential signal attenuation.
2/2006	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel A Haber Research Topics

Disease

103	Neoplasms (Cancer) 01/2022 - 03/2002
23	Circulating Neoplastic Cells 01/2022 - 07/2008
23	Lung Neoplasms (Lung Cancer) 01/2020 - 05/2004
20	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2003
19	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2007
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2010 - 05/2004
9	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 03/2010
9	Carcinogenesis 01/2021 - 03/2003
9	Melanoma (Melanoma, Malignant) 01/2021 - 06/2008
7	Adenocarcinoma 12/2019 - 04/2005
6	Oncogene Addiction 02/2015 - 02/2006
5	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 07/2006
5	Ewing Sarcoma (Sarcoma, Ewing) 11/2014 - 03/2002
5	Wilms Tumor (Wilm's Tumor) 06/2010 - 03/2002
4	Disease Progression 11/2014 - 08/2007
3	Desmoplastic Small Round Cell Tumor 06/2008 - 12/2002
2	Brain Neoplasms (Brain Tumor) 12/2020 - 11/2014
2	Rhabdomyosarcoma 01/2019 - 05/2009
2	Sarcoma (Soft Tissue Sarcoma) 01/2017 - 05/2009
2	Ataxia Telangiectasia (Louis Bar Syndrome) 02/2012 - 08/2004
2	Genetic Translocation (Chromosomal Translocation) 06/2008 - 05/2008
2	Warts (Wart) 04/2008 - 08/2002
2	Shock 03/2007 - 07/2006
2	Head and Neck Neoplasms (Head and Neck Cancer) 02/2007 - 11/2005
2	Ovarian Neoplasms (Ovarian Cancer) 07/2005 - 03/2003
1	Hypoxia (Hypoxemia) 12/2020
1	Starvation 10/2020
1	Osteoporosis 01/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2019
1	Neoplasm Micrometastasis 01/2019

Drug/Important Bio-Agent (IBA)

24	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2010
24	ErbB Receptors (EGF Receptor)IBA 11/2008 - 05/2004
22	Pharmaceutical PreparationsIBA 01/2022 - 08/2004
21	Phosphotransferases (Kinase)IBA 01/2022 - 08/2004
19	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2002
15	Tyrosine Kinase InhibitorsIBA 03/2016 - 05/2004
12	Gefitinib (Iressa)FDA Link 05/2008 - 05/2004
11	Biomarkers (Surrogate Marker)IBA 01/2020 - 12/2007
10	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 02/2007
9	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2015 - 05/2005
7	Biological ProductsIBA 10/2017 - 11/2005
6	LigandsIBA 07/2021 - 03/2002
6	Transcription Factors (Transcription Factor)IBA 02/2012 - 03/2002
5	Estrogen ReceptorsIBA 07/2021 - 06/2004
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 03/2012
4	Small Interfering RNA (siRNA)IBA 12/2020 - 09/2003
4	olaparibIBA 01/2020 - 11/2014
4	EpitopesIBA 01/2020 - 04/2013
4	Androgen Receptors (Androgen Receptor)IBA 01/2018 - 11/2012
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2010 - 05/2004
3	Epithelial Cell Adhesion MoleculeIBA 01/2022 - 04/2012
3	ChromatinIBA 10/2021 - 06/2010
3	AndrogensIBA 01/2018 - 11/2012
3	Circulating Tumor DNAIBA 03/2016 - 06/2014
3	MicroRNAs (MicroRNA)IBA 09/2015 - 06/2006
3	Tamoxifen FDA LinkGeneric 05/2014 - 06/2004
3	Protein Kinases (Protein Kinase)IBA 07/2013 - 08/2002
3	Protein Isoforms (Isoforms)IBA 07/2010 - 11/2004
3	AgarIBA 08/2007 - 12/2002
2	Hormones (Hormone)IBA 07/2021 - 06/2004
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2014
2	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2020
2	Temozolomide (Temodar)FDA LinkGeneric 10/2019 - 01/2019
2	neratinibIBA 01/2019 - 05/2005
2	Mitogen-Activated Protein KinasesIBA 01/2019 - 07/2013
2	Mechanistic Target of Rapamycin Complex 1IBA 07/2014 - 07/2013
2	MitogensIBA 07/2013 - 06/2008
2	Oncogene Proteins (Oncogene Protein)IBA 11/2012 - 07/2006
2	Histones (Histone)IBA 02/2012 - 06/2006
2	CrizotinibIBA 12/2011 - 10/2010
2	Anaplastic Lymphoma KinaseIBA 10/2010 - 05/2008
2	Long-Acting Thyroid Stimulator (LATS)IBA 04/2008 - 08/2002
2	Growth Factor ReceptorsIBA 04/2006 - 02/2006
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	Aromatase InhibitorsIBA 07/2021
1	AntioxidantsIBA 01/2021
1	Vitamin E FDA LinkGeneric 01/2021
1	Transferrin (beta 2 Transferrin)IBA 01/2021
1	IronIBA 01/2021
1	ferrostatin-1IBA 01/2021
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2020
1	Alendronate (Alendronate Sodium)FDA LinkGeneric 01/2020
1	AntigensIBA 01/2020
1	folfirinoxIBA 12/2019
1	Dinoprostone (PGE2)FDA Link 01/2019
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2019
1	ProlactinIBA 01/2019
1	Celecoxib (Celebrex)FDA Link 01/2019
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2019
1	Prolactin Receptors (Prolactin Receptor)IBA 01/2019

Therapy/Procedure

37	Therapeutics 01/2022 - 02/2006
6	Drug Therapy (Chemotherapy) 10/2020 - 02/2007
5	Lab-On-A-Chip Devices 05/2016 - 07/2008
3	Castration 01/2018 - 11/2012
2	Aftercare (After-Treatment) 08/2015 - 07/2013
1	Injections 12/2020
1	Surgical Instruments (Clip) 01/2020
1	Combination Drug Therapy (Combination Chemotherapy) 12/2019
1	Cell Transplantation 01/2019
1	Neoadjuvant Therapy 10/2018